These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2189956)

  • 1. Chemotherapy for advanced aggressive lymphoma: more is better ...isn't it?
    Longo DL
    J Clin Oncol; 1990 Jun; 8(6):952-5. PubMed ID: 2189956
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?
    Coiffier B
    J Clin Oncol; 2003 Jul; 21(13):2457-9. PubMed ID: 12829662
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diffuse large-cell non-Hodgkin's lymphoma. Historical development of polychemotherapy protocols].
    Sánchez Fayos J
    Rev Clin Esp; 1986 Jun; 179(2):85-93. PubMed ID: 3526434
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse large-cell lymphoma: more CHOP-Bleo is not better.
    Coltman CA
    J Clin Oncol; 1986 Oct; 4(10):1439-40. PubMed ID: 2428946
    [No Abstract]   [Full Text] [Related]  

  • 6. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
    Dreyling M
    Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of childhood non-Hodgkin's lymphoma with a multi-drug combination protocol including high-dose methotrexate and citrovorum factor rescue. Children's Cancer and Leukemia Study group].
    Sasaki K; Kawai S; Fujimoto T; Ninomiya T; Kikuchi M; Mitsui T; Yanai M; Komazawa M; Okada T; Utsumi J
    Rinsho Ketsueki; 1985 May; 26(5):721-30. PubMed ID: 3903256
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose-response is alive and well.
    DeVita VT
    J Clin Oncol; 1986 Aug; 4(8):1157-9. PubMed ID: 3525764
    [No Abstract]   [Full Text] [Related]  

  • 9. Dose intensity in poor risk lymphomas: a critical factor in LNH-87 protocol?
    Lepage E
    Pathol Biol (Paris); 1993 Jan; 41(1):103. PubMed ID: 8316442
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of malignant lymphoma in Jichi Medical School Hospital. 3) Treatment of advanced bad-risk lymphoma with the M-CHOP regimen].
    Furukawa Y; Takagi S; Tsuboyama A; Tsunoda S; Komatsu N; Takeda K; Muroi K; Ohsaka A; Miwa A; Yoshida M
    Rinsho Ketsueki; 1988 Jun; 29(6):833-9. PubMed ID: 3418885
    [No Abstract]   [Full Text] [Related]  

  • 11. [VCP therapy for non-Hodgkin's lymphoma advanced more than stage IIB].
    Kuraishi Y; Ozeki H; Takasaki N; Mashizu N; Nagamine D; Usui N; Yamazaki H; Nakamura T; Aiba K; Yokoyama K
    Rinsho Ketsueki; 1984 Nov; 25(11):1731-7. PubMed ID: 6543455
    [No Abstract]   [Full Text] [Related]  

  • 12. [Chemotherapy in advanced non-Hodgkin's lymphoma: follow-up studies].
    Kimura I
    Nihon Rinsho; 1983 Nov; 41(11):2600-10. PubMed ID: 6200629
    [No Abstract]   [Full Text] [Related]  

  • 13. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of non-Hodgkin's lymphoma in the aged].
    Mori M; Kurata K; Ikebuchi K; Fukayama M; Miwa A; Murai Y; Shimada H
    Rinsho Ketsueki; 1985 Sep; 26(9):1458-62. PubMed ID: 3878893
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of malignant lymphoma].
    Shimoyama M
    Gan No Rinsho; 1989 Jan; Spec No():593-604. PubMed ID: 2783748
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
    Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
    Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
    Hosomi Y; Shibuya M
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1352-6. PubMed ID: 11681241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial chemotherapy doses for elderly patients with malignant lymphoma.
    O'Connell MJ; Earle JD; Harrington DP; Johnson GJ; Glick JH
    J Clin Oncol; 1986 Sep; 4(9):1418. PubMed ID: 3746377
    [No Abstract]   [Full Text] [Related]  

  • 19. The Norton-Simon hypothesis revisited.
    Norton L; Simon R
    Cancer Treat Rep; 1986 Jan; 70(1):163-9. PubMed ID: 3510732
    [No Abstract]   [Full Text] [Related]  

  • 20. Low dose continuous chemotherapy (LD56): an active treatment with low toxicity for patients with recurrent/refractory lymphoma not eligible for intensive salvage therapy.
    Intermesoli T; Shamash J; Rohatiner A; Wilson A; Lister A; Montoto S
    Br J Haematol; 2009 Nov; 147(3):408-10. PubMed ID: 19664002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.